In July  the Food and Drug Administration approved AstraZeneca PLCs anticlotting drug Brilinta for patients with certain severe coronary conditions A study had shown the pill saved lives and reduced heart attacksa real eyeopener in medicine But behind the scenes a drama is unfolding over whether the drug should have been approved In a sealed complaint filed in US district court in the District of Columbia Victor Serebruany an adjunct medical professor at Johns Hopkins Hospital who specializes in such drugs
  